A phase II clinical trial conducted in South Africa has confirmed that the therapeutic Tat vaccine against HIV/AIDS can effectively improve the response to antiretroviral drugs in people living with HIV. The results are published today in the peer-review open access journal Retrovirology: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T-cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial
After embargo, article is available at journal website here: http://retrovirology.biomedcentral.com/articles/10.1186/s12977-016-0261-1
A vaccine containing a protein necessary for virus replication can boost an HIV-infected patient’s immune system, according to clinical research published in the open access journal Retrovirology. This boost can result in increased effectiveness of antiretroviral drugs.
State of Art of Anti-HIV/AIDS Vaccine Clinical Trials based on the recombinant biologically active HIV-1 Tat protein sponsored by ISS updated on april 1st 2014.
Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.
Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...
© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information
Informiamo i visitatori, in virtù della individuazione delle modalità semplificate per l'informativa e l'acquisizione del consenso per l'uso dei cookie - 8 maggio 2014 (Pubblicato sulla Gazzetta Ufficiale n. 126 del 3 giugno 2014), che questo sito utilizza direttamente solo cookie tecnici.[Ho letto]